Integration of pharmacotherapies in the existing programs for the treatment of alcoholics: An international perspective

Journal of Addictive Diseases

Volumn 16, Issue 4, 1997, Pages 65-82

  Poldrugo, Flavio ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ALCOHOL; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; APOMORPHINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CALCIUM CHANNEL BLOCKING AGENT; CLOMETHIAZOLE; DISULFIRAM; LITHIUM; METADOXINE; NALOXONE; NALTREXONE; TIAPRIDE; VILOXAZINE;

ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; CHEMOPROPHYLAXIS; COMORBIDITY; HUMAN; PATIENT COUNSELING; PSYCHOTHERAPY; TREATMENT OUTCOME;

ALCOHOL DETERRENTS; ALCOHOL DRINKING; ALCOHOLISM; COMBINED MODALITY THERAPY; EUROPE; FAMILY PRACTICE; HEALTH POLICY; HUMANS; MENTAL HEALTH SERVICES; NARCOTIC ANTAGONISTS; NORTH AMERICA; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0030668152     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550889709511144     Document Type: Article

References (55)

1. Takala JP, Klingemann H, Hunt G. Afterword: common directions and remaining divergences. In: Cure, care, or control. Alcoholism treatment in sixteen countries. Albany: State University of New York Press, 1992:285-304.
2. The Permanent Observatory on Youth and Alcohol. The institutional and regulatory approach. In: Young people and alcohol in Europe. Rome: Edizioni OTET, 1994:55-92.
3. Roemer MI. National health systems as market interventions. Journal of Public Health Policy 1989; 10:62-77.
4. Porter L, Arif AE, Curran WJ. The law and the treatment of drug and alcohol-dependent persons: a comparative study of existing legislation. Geneva:World Health Organization, 1986.
5. Havard JDJ. Alcohol abuse and legislation in Europe. In: L’Alcologia in Europa. Bologna: Editrice Compositori, 1992:1-12.
6. Anderson P. Management of alcohol problems: the role of the general practitioner. Alcohol Alcohol 1993; 28:263-272.
7. Buchsbaum D. Effectiveness of treatment in general medicine patients with drinking problems. Alcohol Health Res World 1994; 18:140-145.
8. Fuller RK. The assessment of treatment outcome. Alcohol J Alcohol Related Addict 1995;31:69-77.
9. Rotter J. Generalized expectancies for internal versus external control of reinforcement. Psychol Monogr 1966; 80:1-28.
10. Poldrugo F, Zorzut G. Factors related to alcoholism relapse in an Italian population. Alcohol J Alcohol Related Addict 1991; 27:57-61.
11. Poldrugo F, Urizzi R. The Italian paradox: treatment initiatives and falling alcohol consumption. In: Cure, care, or control. Alcoholism treatment in sixteen countries. Albany, State University of New York Press, 1992:191-204.
12. Patussi V, Tumino E, Poldrugo F. The development of the Alcoholic Treatment Club system in Italy: fifteen years of experience. Contemp Drug Problems 1996; 23:29-42.
13. Bennett L. Treating alcoholics in a Yugoslav fashion. East Eur Q 1985; 18:495-519.
14. Galanter M. Alcoholism programs in the USSR and Yugoslavia: effects of the social context on treatment. In: Currents in Alcoholism. New York: Grune and Stratton, 1981:183-194.
15. Dole VP, Fishman J, Goldfrank L, et al. Arousal of ethanol-intoxicated comatose patients with naloxone. Alcohol Clin Exp Res 1982; 6:275-279.
16. Burrough AK, Morgan MY, Sherlock S. Double-blind controlled clinical trial of bromocriptine, chlordiazepoxide and chlormethiazole for alcohol withdrawal. Alcohol Alcohol 1985;20:263-271.
17. Bono G, Sinforiani E, Merlo P, et al. Alcoholic abstinence syndromes: short-term treatment with metadoxine. Int J Clin Pharmacol Res 1991; 11:35-40.
18. Poldrugo F, Snead OC. Electroencephalographic and behavioral correlates in rats during repeated ethanol withdrawal syndromes. Psychopharmacology 1984;83:140-146.
19. Butler D, Messiha FS. Alcohol withdrawal and carbamazepine. Alcohol 1986;3:113-129.
20. Minuch GI, Rockman GE, German GB, et al. The use of sodium valproate in the treatment of alcoholism. J Addict Dis 1995; 14:67-74.
21. Shaw G, Majumdar S, Waller S, et al. Tiapride in the long-term management of alcoholics of anxious and depressive temperaments. Br J Psychiatry 1987; 150:164-168.
22. Kraus M, Gottlieb L, Horwitz R, et al. Randomized clinical trial of atenolol in patients with alcohol withdrawal. N Engl J Med 1985; 313:905-909.
23. Cushman P. Clonidine and alcohol withdrawal. Adv Alcohol Subst Abuse 1988; 7:17-28.
24. Palestine M, Alatorre E. Control of acute alcoholic withdrawal symptoms: a comparative study of haloperidol and chlordiazepoxide. Curr Ther Res 1976; 20:289-299.
25. Koppi S, Eberardt G, Haller R, et al. Calcium-channel blocking agents in the treatment of acute withdrawal. Caroverine versus meprobamate in a randomized double-blind study. Neuropsychobiology 1987; 17:49-52.
26. Emrick CD. A review of psychologically oriented treatment of alcoholism. The relative effectiveness of different treatment approaches and the relative effectiveness of treatment versus no treatment. J Stud Alcohol 1975; 36:88-108.
27. Bromet E, Moos RH, Bliss F, et al. Post-treatment functioning of alcoholic patients: its relation to program participation. J Consult Clin Psychol 1977; 45: 829-842.
28. Polich JM, Armor DJ, Braiker HB. The course of alcoholism: four years after treatment. Santa Monica, Rand Corporation, 1980.
29. Feurlein W, Kiifner H. A prospective multicentre study of in-patient treatment for alcoholics: 18- and 48-month follow-up. Eur Arch Psychiatr Neurol Sei 1989; 239:144-157.
30. Miller NS (ed): Treatment of the Addictions: Applications of Outcome Research for Clinical Management. New York: Haworth Press, 1995.
31. The Plinius Major Society. Guidelines on evaluation of treatment of alcohol dependence. Alcohol J Alcohol Related Addict 1994;30 (suppl. 1): 1-83.
32. Moos RH, Finney JW, Cronkite RC. Context, coping, and treatment outcome. In: Alcoholism treatment: context, process, and outcome. New York: Oxford University Press, 1990:109-133.
33. Fuller R, Branchey L, Brightwell D, et al. Disulfiram treatment of alcoholism. A Veteran Administration Cooperative Study. JAMA 1986; 256:1449-1455.
34. Allen JP, Litten RZ, Anton R. Measure of alcohol consumption in perspective. In: Measuring alcohol consumption. Psychosocial and biochemical methods. Totowa, Humana Press, 1992:205-226.
35. Vazquez JJ, De Otazu RD, Guillen FJ, et al. Hepatitis induced by drugs used as alcohol aversion therapy. Diagn Histopathology 1983; 6:29-37.
36. Koob G. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sei 1992; 13:177-184.
37. Shaw GK, Waller S, Majumdar SK, et al. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 1994; 165:515-523.
38. Hoes MJ, Vree TB, Guelen PJ. Enhanced plasma concentrations of gamma-hydroxybutyric acid in alcoholics. Br J Addiction 1978; 73:423-424.
39. Mattila MJ, Palva E, Seppala T, et al. Actions and interactions with alcohol of drugs on psychomotor skills: comparison of diazepam and gamma-hydroxybutyric acid. Arch Int Pharmacodyn 1978; 234:236-246.
40. Froehlich JC, Harts J, Lumeng JL, et al. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav 1990; 35:385-390.
41. Volpicelli J, Alterman A, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876-880.
42. O’Malley S, Jaffe A, Chang G, et al. Naltrexone and coping skill therapy for alcohol dependence. Arch Gen Psychiatry 1992; 49:881-887.
43. Mason B, Ritvo E, Morgan R, et al. A double-blind placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCI for alcohol dependence. Alcohol Clin Exp Res 1994; 18:1162-1167.
44. Jensen SB, Christoffersen CB, Noerregaard A. Apomorphine in out-patient treatment of alcohol intoxication and abstinence: a double blind study. Br J Addict 1977;72:325-330.
45. Dorus W, Ostrów DG, Anton R, et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA 1989; 232:1646-1652.
46. Fawcett J, Clark D, Gibbons R, et al. Evaluation of lithium therapy for alcoholism. J Clin Psychiatry 1984; 45:494-499.
47. Lejoyeux M, Ades J. Evaluation of lithium treatment in alcoholism. Alcohol Alcohol 1993;28:273-279.
48. Emrick CD, Tonigan JS, Montgomery H, et al. Alcoholics Anonymous: what is currently known? In: Research on Alcoholics Anonymous. New Brunswick, Canada, Alcohol Research Documentation Inc., 1993:41-76.
49. Miller NS, Hoffmann NG: Addictions treatment outcomes. Alcohol Treat Q 1995; 12:41-55.
50. Potamianos G, North WRS, Meade TW, et al. Randomized trial of community-bascd centre versus conventional hospital management in treatment of alcoholism. Lancet 1986; ii:797-799.
51. Poldrugo F. Evaluation of alcohol treatment programs. In: Proceedings of the international meeting on alcohol and therapy. Gorizia, USL Press, 1993:99-112.
52. Poldrugo F, Chick JD, Moore N, et al. Mortality studies in the long-term evaluation of treatment of alcoholics. Alcohol Alcohol 1993; 28(suppl. 2): 151-155.
53. Pelc I, Le Bon O, Verbanck P, et al. Calcium-acetylhomotaurinate for maintaining abstinence in weaned alcoholic patients: a placebo-controlled, doubleblind, multicenter study. In: Novel pharmacological interventions for alcoholism. New York, Springer Verlag, 1992:348-352.
54. Poldrugo F, Chabac S, Lehert P. Acamprosate in the long-term treatment of alcoholism: is its use recommended within the psycho-social approach? Alcohol Clin Exp Res 1994; 18:43A.
55. Jones SL, Kanfer R, Lanyon RI. Skills training with alcoholics: a clinical extension. Addict Behav 1982; 7:285-290.